



**REPORTED SALES vs. PRIOR PERIOD**

**\$MM**

	FOURTH QUARTER					TWELVE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2)</sup></b>										
<b>ACIPHEX/PARIET</b>										
US	166	157	5.7%	5.7%	-	645	595	8.4%	8.4%	-
Intl	181	161	12.4%	-0.4%	12.8%	712	644	10.6%	2.5%	8.1%
WW	347	318	9.1%	2.6%	6.5%	1,357	1,239	9.5%	5.3%	4.2%
<b>Anti-Psychotics <sup>(3)</sup></b>										
US	722	629	14.8%	14.8%	-	2,759	2,418	14.1%	14.1%	-
Intl	498	432	15.3%	4.5%	10.8%	1,938	1,765	9.8%	2.5%	7.3%
WW	1,220	1,061	15.0%	10.6%	4.4%	4,697	4,183	12.3%	9.2%	3.1%
<b>CONCERTA</b>										
US	222	209	6.2%	6.2%	-	798	756	5.6%	5.6%	-
Intl	67	48	39.6%	26.6%	13.0%	230	174	32.2%	22.8%	9.4%
WW	289	257	12.5%	10.1%	2.4%	1,028	930	10.5%	8.7%	1.8%
<b>DURAGESIC/Fentanyl Transdermal</b>										
US	72	108	-33.3%	-33.3%	-	391	478	-18.2%	-18.2%	-
Intl	192	184	4.3%	-6.2%	10.5%	773	817	-5.4%	-11.7%	6.3%
WW	264	292	-9.6%	-16.2%	6.6%	1,164	1,295	-10.1%	-14.1%	4.0%
<b>EPREX/PROCRIT</b>										
US	331	491	-32.6%	-32.6%	-	1,690	2,064	-18.1%	-18.1%	-
Intl	297	297	0.0%	-11.5%	11.5%	1,195	1,116	7.1%	-1.4%	8.5%
WW	628	788	-20.3%	-24.6%	4.3%	2,885	3,180	-9.3%	-12.3%	3.0%
<b>Hormonal Contraceptives</b>										
US	146	184	-20.7%	-20.7%	-	662	781	-15.2%	-15.2%	-
Intl	69	60	15.0%	2.0%	13.0%	263	235	11.9%	3.9%	8.0%
WW	215	244	-11.9%	-15.1%	3.2%	925	1,016	-9.0%	-10.9%	1.9%
<b>LEVAQUIN/FLOXIN</b>										
US	409	423	-3.3%	-3.3%	-	1,564	1,471	6.3%	6.3%	-
Intl	23	16	43.8%	38.8%	5.0%	82	59	39.0%	37.2%	1.8%
WW	432	439	-1.6%	-1.8%	0.2%	1,646	1,530	7.6%	7.5%	0.1%
<b>REMICADE</b>										
US	661	592	11.7%	11.7%	-	2,534	2,355	7.6%	7.6%	-
Intl <sup>(4)</sup>	247	188	31.4%	31.4%	-	793	658	20.5%	20.5%	-
WW	908	780	16.4%	16.4%	-	3,327	3,013	10.4%	10.4%	-
<b>TOPAMAX</b>										
US	535	429	24.7%	24.7%	-	2,006	1,629	23.1%	23.1%	-
Intl	117	100	17.0%	5.8%	11.2%	447	398	12.3%	4.3%	8.0%
WW	652	529	23.3%	21.2%	2.1%	2,453	2,027	21.0%	19.4%	1.6%
<b>Other</b>										
US	434	458	-5.2%	-5.2%	-	1,764	1,887	-6.5%	-6.5%	-
Intl	1,008	784	28.6%	18.1%	10.5%	3,620	2,967	22.0%	14.8%	7.2%
WW	1,442	1,242	16.1%	9.5%	6.6%	5,384	4,854	10.9%	6.5%	4.4%
<b>Total Pharmaceutical</b>										
US <sup>(4)</sup>	3,944	3,868	2.0%	2.0%	-	15,603	15,092	3.4%	3.4%	-
Intl	2,453	2,082	17.8%	6.8%	11.0%	9,263	8,175	13.3%	5.9%	7.4%
WW	6,397	5,950	7.5%	3.7%	3.8%	24,866	23,267	6.9%	4.3%	2.6%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)

<sup>(3)</sup> Includes Risperdal, Risperdal Consta & Invega

<sup>(4)</sup> Remicade international figures include sales to partners for markets outside the U.S. For total pharmaceutical sales reporting, these sales are reported as domestic sales. Sales to partners outside the U.S. are as follows: Q4: 246, YTD: 790 and 2006 Q4: 188, YTD: 658



REPORTED SALES vs. PRIOR PERIOD

\$MM

	FOURTH QUARTER					TWELVE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES AND DIAGNOSTICS<sup>(2)</sup></b>										
<u>Cordis</u>										
US	394	464	-15.1%	-15.1%	-	1,588	2,033	-21.9%	-21.9%	-
Intl	474	497	-4.6%	-12.3%	7.7%	1,837	2,055	-10.6%	-15.0%	4.4%
WW	868	961	-9.7%	-13.7%	4.0%	3,425	4,088	-16.2%	-18.4%	2.2%
<u>DePuy</u>										
US	661	641	3.1%	3.1%	-	2,638	2,532	4.2%	4.2%	-
Intl	548	419	30.8%	19.0%	11.8%	1,949	1,573	23.9%	15.2%	8.7%
WW	1,209	1,060	14.1%	9.4%	4.7%	4,587	4,105	11.7%	8.4%	3.3%
<u>Ethicon</u>										
US	352	309	13.9%	13.9%	-	1,395	1,252	11.4%	11.4%	-
Intl	591	518	14.1%	3.5%	10.6%	2,196	1,961	12.0%	4.5%	7.5%
WW	943	827	14.0%	7.3%	6.7%	3,591	3,213	11.8%	7.2%	4.6%
<u>Ethicon Endo-Surgery</u>										
US	481	421	14.3%	14.3%	-	1,792	1,632	9.8%	9.8%	-
Intl	583	479	21.7%	10.9%	10.8%	2,042	1,744	17.1%	9.5%	7.6%
WW	1,064	900	18.2%	12.6%	5.6%	3,834	3,376	13.6%	9.9%	3.7%
<u>LifeScan</u>										
US	337	289	16.6%	16.6%	-	1,260	1,146	9.9%	9.9%	-
Intl	306	253	20.9%	8.6%	12.3%	1,113	928	19.9%	11.4%	8.5%
WW	643	542	18.6%	12.9%	5.7%	2,373	2,074	14.4%	10.6%	3.8%
<u>Ortho-Clinical Diagnostics</u>										
US	228	197	15.7%	15.7%	-	881	765	15.2%	15.2%	-
Intl	211	193	9.3%	0.2%	9.1%	761	723	5.3%	-0.7%	6.0%
WW	439	390	12.6%	8.1%	4.5%	1,642	1,488	10.3%	7.4%	2.9%
<u>Total Vision Care</u>										
US	190	157	21.0%	21.0%	-	812	698	16.3%	16.3%	-
Intl	376	314	19.7%	12.8%	6.9%	1,397	1,181	18.3%	15.2%	3.1%
WW	566	471	20.2%	15.6%	4.6%	2,209	1,879	17.6%	15.7%	1.9%
<u>Other</u>										
US	18	13	38.5%	38.5%	-	67	52	28.8%	28.8%	-
Intl	0	3	-100.0%	-381.4%	281.4%	8	8	0.0%	-217.0%	217.0%
WW	18	16	12.5%	11.4%	1.1%	75	60	25.0%	24.2%	0.8%
<u>Total Medical Devices and Diagnostics</u>										
US	2,661	2,491	6.8%	6.8%	-	10,433	10,110	3.2%	3.2%	-
Intl	3,089	2,676	15.4%	5.6%	9.8%	11,303	10,173	11.1%	4.6%	6.5%
WW	5,750	5,167	11.3%	6.2%	5.1%	21,736	20,283	7.2%	3.9%	3.3%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)



**REPORTED SALES vs. PRIOR PERIOD**

**\$MM**

	FOURTH QUARTER					TWELVE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2) (3)</sup></b>										
<u>Skin Care</u>										
US	323	281	14.9%	14.9%	-	1,329	1,144	16.2%	16.2%	-
Intl	470	404	16.3%	5.3%	11.0%	1,722	1,489	15.6%	8.0%	7.6%
WW	793	685	15.8%	9.3%	6.5%	3,051	2,633	15.9%	11.6%	4.3%
<u>Baby &amp; Kids Care</u>										
US	116	102	13.7%	13.7%	-	444	404	9.9%	9.9%	-
Intl	421	359	17.3%	6.8%	10.5%	1,538	1,336	15.1%	7.6%	7.5%
WW	537	461	16.5%	8.4%	8.1%	1,982	1,740	13.9%	8.1%	5.8%
<u>Oral Care</u>										
US	189	69	173.9%	173.9%	-	789	247	219.4%	219.4%	-
Intl	190	44	331.8%	321.7%	10.1%	699	159	339.6%	332.6%	7.0%
WW	379	113	235.4%	231.4%	4.0%	1,488	406	266.5%	263.7%	2.8%
<u>OTC/Nutritionals</u>										
US	728	530	37.4%	37.4%	-	2,620	1,870	40.1%	40.1%	-
Intl	687	227	202.6%	190.5%	12.1%	2,522	872	189.2%	181.1%	8.1%
WW	1,415	757	86.9%	83.3%	3.6%	5,142	2,742	87.5%	84.9%	2.6%
<u>Women's Health</u>										
US	148	140	5.7%	5.7%	-	623	588	6.0%	6.0%	-
Intl	313	280	11.8%	0.2%	11.6%	1,183	1,078	9.7%	1.7%	8.0%
WW	461	420	9.8%	2.1%	7.7%	1,806	1,666	8.4%	3.2%	5.2%
<u>Other</u>										
US	122	60	103.3%	103.3%	-	603	320	88.4%	88.4%	-
Intl	103	69	49.3%	38.6%	10.7%	421	267	57.7%	50.2%	7.5%
WW	225	129	74.4%	68.7%	5.7%	1,024	587	74.4%	71.0%	3.4%
<u>Total Consumer</u>										
US	1,626	1,182	37.6%	37.6%	-	6,408	4,573	40.1%	40.1%	-
Intl	2,184	1,383	57.9%	46.8%	11.1%	8,085	5,201	55.5%	47.8%	7.7%
WW	3,810	2,565	48.5%	42.5%	6.0%	14,493	9,774	48.3%	44.2%	4.1%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)

<sup>(3)</sup> 2007 Includes sales from acquisition of PCH